Treatment of disseminated malignant melanoma with high‐dose oral BCG
Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients,...
Gespeichert in:
Veröffentlicht in: | Cancer 1981-09, Vol.48 (6), p.1353-1362 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1362 |
---|---|
container_issue | 6 |
container_start_page | 1353 |
container_title | Cancer |
container_volume | 48 |
creator | Varella, Antonio Drauzio Bandiera, Dino Carlos De Amorim, Antonio R. Calvis, Luciano A. Santos, Ivan Oliveira Escaleira, Narcisco Gentil, Fernando |
description | Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six‐month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal. |
doi_str_mv | 10.1002/1097-0142(19810915)48:6<1353::AID-CNCR2820480617>3.0.CO;2-N |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15450655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15450655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5007-8964c9b66667c7a8d8d971e3219595a483df4a76f30590f6b4e3fc539de1e2813</originalsourceid><addsrcrecordid>eNqVkN1q20AQhZfSkLhpH6Ggq9BeyJn91a5bCqnyC8GGkkKhF8NaGsUqkpVqZULu-gh9xjxJ1tgJNBeBzs0wnJlzho-xnMOYA4hDDi5LgSvxgTsbB64_Kjsxn7nUcjI5ujhO82n-TVgByoLh2Rc5hnE--yTS6Ss2erp-zUYAYFOt5I899iaEX3HMhJa7bDcDIY1WI3Z61ZMfWloOSVclZR0CtfXSD1QmrW_q66WPSkuNX3atT27rYZEs6uvF_Z-_ZRco6XrfJF_zs7dsp_JNoHfbvs--n55c5efp5ezsIj-6TAsds1PrjCrc3MTKiszb0pYu4yQFd9ppr6wsK-UzU0nQDiozVySrQktXEidhudxnBxvfm777vaIwYFuHgpr4H3WrgFwrDUbruPhzs1j0XQg9VXjT163v75ADrinjmhOuOeEjZVQWDa4pI0bK-C9llAiYz1DgNLq_376xmrdUPnlvsUa92ui3dUN3_xf9YvIzRT4AUKyZyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15450655</pqid></control><display><type>article</type><title>Treatment of disseminated malignant melanoma with high‐dose oral BCG</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Varella, Antonio Drauzio ; Bandiera, Dino Carlos ; De Amorim, Antonio R. ; Calvis, Luciano A. ; Santos, Ivan Oliveira ; Escaleira, Narcisco ; Gentil, Fernando</creator><creatorcontrib>Varella, Antonio Drauzio ; Bandiera, Dino Carlos ; De Amorim, Antonio R. ; Calvis, Luciano A. ; Santos, Ivan Oliveira ; Escaleira, Narcisco ; Gentil, Fernando</creatorcontrib><description>Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six‐month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19810915)48:6<1353::AID-CNCR2820480617>3.0.CO;2-N</identifier><identifier>PMID: 7023654</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Administration, Oral ; Adult ; Aged ; BCG Vaccine - administration & dosage ; BCG Vaccine - therapeutic use ; Clinical Trials as Topic ; Female ; Humans ; Male ; Melanoma - pathology ; Melanoma - therapy ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy</subject><ispartof>Cancer, 1981-09, Vol.48 (6), p.1353-1362</ispartof><rights>Copyright © 1981 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c5007-8964c9b66667c7a8d8d971e3219595a483df4a76f30590f6b4e3fc539de1e2813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7023654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Varella, Antonio Drauzio</creatorcontrib><creatorcontrib>Bandiera, Dino Carlos</creatorcontrib><creatorcontrib>De Amorim, Antonio R.</creatorcontrib><creatorcontrib>Calvis, Luciano A.</creatorcontrib><creatorcontrib>Santos, Ivan Oliveira</creatorcontrib><creatorcontrib>Escaleira, Narcisco</creatorcontrib><creatorcontrib>Gentil, Fernando</creatorcontrib><title>Treatment of disseminated malignant melanoma with high‐dose oral BCG</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six‐month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>BCG Vaccine - administration & dosage</subject><subject>BCG Vaccine - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Melanoma - pathology</subject><subject>Melanoma - therapy</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Prognosis</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1981</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkN1q20AQhZfSkLhpH6Ggq9BeyJn91a5bCqnyC8GGkkKhF8NaGsUqkpVqZULu-gh9xjxJ1tgJNBeBzs0wnJlzho-xnMOYA4hDDi5LgSvxgTsbB64_Kjsxn7nUcjI5ujhO82n-TVgByoLh2Rc5hnE--yTS6Ss2erp-zUYAYFOt5I899iaEX3HMhJa7bDcDIY1WI3Z61ZMfWloOSVclZR0CtfXSD1QmrW_q66WPSkuNX3atT27rYZEs6uvF_Z-_ZRco6XrfJF_zs7dsp_JNoHfbvs--n55c5efp5ezsIj-6TAsds1PrjCrc3MTKiszb0pYu4yQFd9ppr6wsK-UzU0nQDiozVySrQktXEidhudxnBxvfm777vaIwYFuHgpr4H3WrgFwrDUbruPhzs1j0XQg9VXjT163v75ADrinjmhOuOeEjZVQWDa4pI0bK-C9llAiYz1DgNLq_376xmrdUPnlvsUa92ui3dUN3_xf9YvIzRT4AUKyZyQ</recordid><startdate>19810915</startdate><enddate>19810915</enddate><creator>Varella, Antonio Drauzio</creator><creator>Bandiera, Dino Carlos</creator><creator>De Amorim, Antonio R.</creator><creator>Calvis, Luciano A.</creator><creator>Santos, Ivan Oliveira</creator><creator>Escaleira, Narcisco</creator><creator>Gentil, Fernando</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19810915</creationdate><title>Treatment of disseminated malignant melanoma with high‐dose oral BCG</title><author>Varella, Antonio Drauzio ; Bandiera, Dino Carlos ; De Amorim, Antonio R. ; Calvis, Luciano A. ; Santos, Ivan Oliveira ; Escaleira, Narcisco ; Gentil, Fernando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5007-8964c9b66667c7a8d8d971e3219595a483df4a76f30590f6b4e3fc539de1e2813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1981</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>BCG Vaccine - administration & dosage</topic><topic>BCG Vaccine - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Melanoma - pathology</topic><topic>Melanoma - therapy</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Prognosis</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Varella, Antonio Drauzio</creatorcontrib><creatorcontrib>Bandiera, Dino Carlos</creatorcontrib><creatorcontrib>De Amorim, Antonio R.</creatorcontrib><creatorcontrib>Calvis, Luciano A.</creatorcontrib><creatorcontrib>Santos, Ivan Oliveira</creatorcontrib><creatorcontrib>Escaleira, Narcisco</creatorcontrib><creatorcontrib>Gentil, Fernando</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Varella, Antonio Drauzio</au><au>Bandiera, Dino Carlos</au><au>De Amorim, Antonio R.</au><au>Calvis, Luciano A.</au><au>Santos, Ivan Oliveira</au><au>Escaleira, Narcisco</au><au>Gentil, Fernando</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of disseminated malignant melanoma with high‐dose oral BCG</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1981-09-15</date><risdate>1981</risdate><volume>48</volume><issue>6</issue><spage>1353</spage><epage>1362</epage><pages>1353-1362</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six‐month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>7023654</pmid><doi>10.1002/1097-0142(19810915)48:6<1353::AID-CNCR2820480617>3.0.CO;2-N</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-543X |
ispartof | Cancer, 1981-09, Vol.48 (6), p.1353-1362 |
issn | 0008-543X 1097-0142 |
language | eng |
recordid | cdi_proquest_miscellaneous_15450655 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Administration, Oral Adult Aged BCG Vaccine - administration & dosage BCG Vaccine - therapeutic use Clinical Trials as Topic Female Humans Male Melanoma - pathology Melanoma - therapy Middle Aged Neoplasm Metastasis Prognosis Skin Neoplasms - pathology Skin Neoplasms - therapy |
title | Treatment of disseminated malignant melanoma with high‐dose oral BCG |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T07%3A55%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20disseminated%20malignant%20melanoma%20with%20high%E2%80%90dose%20oral%20BCG&rft.jtitle=Cancer&rft.au=Varella,%20Antonio%20Drauzio&rft.date=1981-09-15&rft.volume=48&rft.issue=6&rft.spage=1353&rft.epage=1362&rft.pages=1353-1362&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(19810915)48:6%3C1353::AID-CNCR2820480617%3E3.0.CO;2-N&rft_dat=%3Cproquest_cross%3E15450655%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15450655&rft_id=info:pmid/7023654&rfr_iscdi=true |